| Autor: |
Araf S; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK. s.araf@qmul.ac.uk.; Centre for Genomic Health, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk., Wang J; Centre for Molecular Oncology, Barts Cancer Institute, London, UK., Korfi K; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Pangault C; UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France., Kotsiou E; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Rio-Machin A; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Rahim T; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Heward J; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Clear A; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Iqbal S; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Davies JK; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Johnson P; Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK., Calaminici M; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Montoto S; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Auer R; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Chelala C; Centre for Molecular Oncology, Barts Cancer Institute, London, UK., Gribben JG; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Graham TA; Evolution and Cancer Laboratory, Barts Cancer Institute, London, UK., Fest T; UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France., Fitzgibbon J; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK., Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, London, UK. j.okosun@qmul.ac.uk. |
Full text from SpringerLink